Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Taltz ® (ixekizumab) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
At this time, Lilly has not studied the use of ixekizumab in patients with coronavirus disease 2019 (COVID-19).
Ixekizumab should not be used during active COVID-19 infection and may be resumed after medical consultation and infection is resolved.1
If COVID-19 is confirmed, ixekizumab should be immediately discontinued and may be resumed after medical consultation and infection is resolved.1
If COVID-19 infection is suspected and signs and symptoms of acute infection occur, the patient should consult with their healthcare provider and seek medical advice for guidance on continuing and initiating ixekizumab treatment.1
Use of Ixekizumab in High Risk Areas
At this time, Lilly has not studied the use of ixekizumab in patients at risk of contracting COVID-19.
COVID-19 is an active respiratory infection, which is typically mild and may also lead to acute respiratory distress syndrome which can be lethal.1
Infectious Disease Resources
For the most current information regarding COVID-19 and Coronavirus, please refer to the websites of local health authorities and/or WHO at WHO Coronavirus disease (COVID-19) outbreak.
Ixekizumab Infection-Related Warnings and Precautions according to the SmPC
Ixekizumab is contraindicated in patients with clinically important active infections (e. g. active tuberculosis).2
Treatment with ixekizumab is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections.2
Ixekizumab should be used with caution in patients with clinically important chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If an infection develops, monitor carefully and discontinue ixekizumab if the patient is not responding to standard therapy or the infection becomes serious. Ixekizumab should not be resumed until the infection resolves.2
Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.2
Ixekizumab, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.2
Ixekizumab is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.2
Ixekizumab is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).2
Lilly = Eli Lilly and Company
WHO = World Health Organization
Datum fӧr senaste ӧversyn 2020 M02 25